The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Genetic risk factors for inhibitors to factors VIII and IX
Abstract
Summary. The formation of alloantibodies against factor VIII (FVIII) or factor IX (FIX) is the most severe complication of replacement therapy in patients with haemophilia. In the last decade, genetic factors have been shown to constitute a decisive risk determinant for the development of inhibitors. In severe haemophilia A and B, mutations that result in an absent or truncated FVIII/FIX protein are associated with a 20–80% risk of inhibitor formation. In mild to moderate haemophilia, missense mutations represent the main mutation type, with an inhibitor prevalence of 5%. These patients synthesize some endogenous, although non‐functional protein that is sufficient to induce immune tolerance. However, in patients with missense mutations clustered in the A2 and C2 domains (C1/C2 junction), the risk of inhibitor formation is fourfold greater than in patients with mutations outside this region, indicating that inhibitor prevalence in missense mutations is also dependent on localization of the mutation. Recently, a significant association between inhibitor formation and polymorphisms in genes coding for cytokines (IL‐10) and other immunoregulatory factors (TNF‐α) has been shown. These genetic factors constitute the individual genetic risk profile of a haemophilic patient. This risk is imprinted and fixed; however, environmental factors such as treatment schedule may increase or decrease the inhibitor risk in an individual patient. Improved understanding of these complex interactions may lead to the development of preventive measures to minimize inhibitor formation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CD28/B7 SYSTEM OF T CELL COSTIMULATION
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717
The Pathophysiology Of Tumor Necrosis Factors
VASSALLI, P. (1992) · Annual Review of Immunology · doi:10.1146/annurev.immunol.10.1.411 · Cited by 1,920
MHC ligands and peptide motifs: first listing
Rammensee, H.-G., Friede, T., & Stevanović, S. (1995) · Immunogenetics · doi:10.1007/bf00172063 · Cited by 1,638
Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes
Rousset, F., Garcia, E., Defrance, T., Péronne, C., Vezzio, N., Hsu, D. H., Kastelein, R., Moore, K. W., & Banchereau, J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1890 · Cited by 1,238
Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation
Schwaab, R., Brackmann, H.-H., Meyer, C., Seehafer, J., Kirchgesser, M., Haack, A., Olek, K., Tuddenham, E. G. D., & Oldenburg, J. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649954 · Cited by 331
Self-citationAstermark, J., Oldenburg, J., Pavlova, A., Berntorp, E., Lefvert, A.-K., & for the MIBS Study Group (2006) · Blood · doi:10.1182/blood-2005-09-3918 · Cited by 268
Self-citationThe factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4
Kemball-Cook, G. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.216 · Cited by 233
Astermark, J., Berntorp, E., White, G. C., Kroner, B. L., & THE MIBS STUDY GROUP (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00510.x · Cited by 207
Scharrer, Bray, & Neutzling (1999) · Haemophilia · doi:10.1046/j.1365-2516.1999.00300.x · Cited by 200
Oldenburg, J., Picard, J. K., Schwaab, R., Brackmann, H. H., Tuddenham, E. G. D., & Simpson, E. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1655945 · Cited by 197
Self-citationHay, C. R. M., Oilier, W., Pepper, L., Cumming, A., Keeney, S., Goodeve, A. C., Colvin, B. T., Hill, F. G. H., Preston, F. E., Peake, I. R., et al. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1655944 · Cited by 190
Factor VIII Inhibitors in Mild and Moderate-severity Haemophilia A
Ludlam, C. A., Colvin, B. T., Hill, F. G. H., Preston, F. E., Wasseem, N., Bagnall, R., Peake, I. R., Berntorp, E., Bunschoten, E. P. M., Fijnvandraat, K., et al. (1998) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615061 · Cited by 187
Hay, C. R. M., Ludlam, C. A., Colvin, B. T., Hill, F. G. H., Preston, F. E., Wasseem, N., Bagnall, R. D., Peake, I. R., Berntorp, E. E., Mauser‐Bunschoten, E. P., et al. (1998) · PubMed · Cited by 186
Factor IX Inhibitors and Anaphylaxis in Hemophilia B
Warrier, I., Ewenstein, B. M., Koerper, M. A., Shapiro, A., Key, N., DiMichele, D., Miller, R. T., Pasi, J., Rivard, G. E., Sommer, S. S., et al. (1997) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199701000-00003 · Cited by 183
Inhibitor development in correlation to factor VIII genotypes
Oldenburg, J., El‐Maarri, O., & Schwaab, R. (2002) · Haemophilia · doi:10.1046/j.1351-8216.2001.00134.x · Cited by 171
Self-citationPrevention and treatment of factor VIII inhibitors in murine hemophilia A
Qian, J., Collins, M., Sharpe, A. H., & Hoyer, L. W. (2000) · Blood · doi:10.1182/blood.v95.4.1324.004k25_1324_1329 · Cited by 168
Haemophilia B: database of point mutations and short additions and deletions--eighth edition
Giannelli, F., Green, P. M., Sommer, S. S., Poon, M., Ludwig, M. Z., Schwaab, R., Reitsma, P. H., Goossens, M., Yoshioka, A., Figueiredo, M. S., et al. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.265 · Cited by 162
Molecular etiology of factor VIII deficiency in hemophilia A
Antonarakis, S. E., Kazazian, H. H., & Tuddenham, E. G. D. (1995) · Human Mutation · doi:10.1002/humu.1380050102 · Cited by 147
Becker, J., Schwaab, R., Möller-Taube, A., Schwaab, U., Schmidt, W. K., Brackmann, H., Grimm, T., Olek, K., & Oldenburg, J. (1996) · PubMed · Cited by 144
Self-citationFactor VIII inhibitors in mild and moderate‐severity haemophilia A
Lee, C. A., Kessler, C. M., Varon, D., Martinowitz, U. P., Heim, M., & Hay, C. R. M. (1998) · Haemophilia · doi:10.1046/j.1365-2516.1998.440558.x · Cited by 136
Liu, M., Shen, B. W., Nakaya, S. M., Pratt, K. P., Fujikawa, K., Davie, E. W., Stoddard, B. L., & Thompson, A. R. (2000) · Blood · doi:10.1182/blood.v96.3.979 · Cited by 127
Tumor necrosis factor α in autoimmunity: pretty girl or old witch?
Jacob, C. O. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90107-i · Cited by 126
The Endogenous Pathway of MHC Class II Antigen Presentation
Lechler, R. I., Aichinger, G., & Lightstone, L. (1996) · Immunological Reviews · doi:10.1111/j.1600-065x.1996.tb00703.x · Cited by 103
Reding, M. T., Wu, H., Krampf, M. R., Okita, D. K., Diethelm-Okita, B. M., Christie, B. A., Key, N. S., & Conti‐Fine, B. M. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614081 · Cited by 100
OLDENBURG, J., ESCOBAR, M., BERNTORP, E., MIBS study group, Astermark, J., & White, G. (2005) · PubMed · doi:10.17615/tepe-nx20 · Cited by 94
Self-citationMolecular genotyping of the Italian cohort of patients with hemophilia B.
Belvini, D., Salviato, R., Radossi, P., Pierobon, F., Mori, P., Castaldo, G., & Tagariello, G. (2005) · PubMed · Cited by 90
Peerlinck, K., Jacquemin, M. G., Arnout, J., Hoylaerts, M., Gilles, J. G., Lavend’homme, R., Johnson, K. M., Freson, K., Scandella, D. H., Saint-Remy, J.-M., et al. (1999) · Blood · doi:10.1182/blood.v93.7.2267 · Cited by 90
The Role of Genetics in Inhibitor Formation
Gill, J. C. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615871 · Cited by 84
White, G. C., Kempton, C. L., GRIMSLEY, A., Nielsen, B., & Roberts, H. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01375.x · Cited by 82
CD4+ T Cell Response to Factor VIII in Hemophilia A, Acquired Hemophilia, and Healthy Subjects
Reding, M. T., Wu, H., Krampf, M. R., Okita, D. K., Diethelm-Okita, B. M., Key, N. S., & Conti‐Fine, B. M. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615873 · Cited by 71
Immunochemical characterization of factor VIII inhibitors.
Lw, H., Gawryl, M. S., & de la Fuente, B. (1984) · PubMed · Cited by 65
Gene Mutations and Inhibitor Formation in Patients with Hemophilia B
Ljung, R. C. R. (2009) · Acta Haematologica · doi:10.1159/000204029 · Cited by 53
Kreuz, W., Becker, S., Lenz, E., Martinez‐Saguer, I., Escuriola-Ettingshausen, C., Funk, M. B., Ehrenforth, S., Auerswald, G., & Kornhuber, B. (1995) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2007-1000659 · Cited by 48
Cited by
Iorio, A., Spencer, F. A., Falavigna, M., Alba, C., Lang, E., Burnand, B., McGinn, T., Hayden, J., Williams, K., Shea, B., et al. (2015) · BMJ · doi:10.1136/bmj.h870 · Cited by 880
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants
Kishnani, P. S., Goldenberg, P. C., DeArmey, S. L., Heller, J., Benjamin, D., Young, S., Bali, D., Smith, S. A., Li, J. S., Mandel, H., et al. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.08.003 · Cited by 383
Oldenburg, J. (2015) · Blood · doi:10.1182/blood-2015-01-528414 · Cited by 376
Self-citationFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
Rath, T., Baker, K., Dumont, J. A., Peters, R. T., Jiang, H., Qiao, S.-W., Lencer, W. I., Pierce, G. F., & Blumberg, R. S. (2015) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.834293 · Cited by 281
Metadata
- Authors
- OLDENBURG, J., & PAVLOVA, A.
- Venue
- Haemophilia
- Publisher
- Wiley
- Published
- 2006-11-10
- Volume
- 12
- Issue
- s6
- Pages
- 15-22
- ISSN
- 1351-8216 (ISSN-L)
- 1365-2516
- OpenAlex
- W2128487729
- Cited by
- 256
- References
- 33
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.